Skip to content

Hero image: Three generations of a family reviewing a pedigree with a genetic counsellor

All insights

Strength & Safeguard

Hereditary Breast and Ovarian Cancer: Turning One Result Into Family Prevention

10 min readEvidence synthesis
Read the evidence

The question in focus

An evidence-based guide to hereditary breast and ovarian cancer risk assessment, genetic counselling, BRCA testing, variants and cascade testing.

Evidence at a glance

>60%

estimated lifetime breast-cancer risk with a harmful BRCA1 or BRCA2 variant

NCI contrasts this with about 13% in the general female population. Individual risk varies by gene, variant, family history and other factors.

BRCA Gene Changes: Cancer Risk and Genetic Testing

Hereditary risk is a family pattern, not a single cancer

BRCA1 and BRCA2 help repair DNA. A harmful inherited variant can increase risks of breast, ovarian, fallopian-tube, primary peritoneal and some other cancers. NCI estimates that more than 60% of women with a harmful BRCA1 or BRCA2 variant will develop breast cancer during their lifetime, compared with about 13% in the general female population [1]. This is a population estimate, not an individual's destiny.

Clues include ovarian cancer, young breast cancer, multiple related cancers, male breast cancer, pancreatic or metastatic prostate cancer, a known family variant and certain ancestries. A three-generation pedigree should record cancer type, age at diagnosis, both sides of the family and pathology where available. Small families, adoption, early deaths and limited knowledge can hide inherited risk.

  • Assess maternal and paternal family history equally.
  • Confirm tumour type and age where records are available.
  • Update family history as new diagnoses occur.

Testing begins with counselling and the right person

The USPSTF recommends a validated brief familial risk tool for women with relevant personal or family history or ancestry, followed by genetic counselling and testing when indicated [2]. When possible, testing an affected relative first is more informative because it can identify the familial variant. If no affected relative is available, a genetics professional can explain what a negative result can and cannot exclude.

Modern panels may include BRCA1, BRCA2, PALB2, RAD51C, RAD51D, BRIP1 and mismatch-repair genes, selected according to history and guideline criteria. Broader is not automatically better. Panels increase the chance of a variant of uncertain significance, which should not be managed as a pathogenic variant. Results need interpretation in the context of laboratory classification, family history and current guidance [3].

  • Ask whether testing an affected relative first is possible.
  • Choose a panel with a clear clinical rationale.
  • Do not use a variant of uncertain significance to justify risk-reducing surgery.

A negative consumer test may be falsely reassuring

NCI notes that the FDA-authorised direct-to-consumer inherited-cancer test assesses three BRCA variants common in Ashkenazi Jewish populations, while hundreds of harmful BRCA variants exist. NCI estimates that this limited approach misses about 80% of cancer-causing BRCA variants [4]. A negative consumer result therefore does not rule out hereditary cancer for most people.

Clinical testing should be performed in an appropriately accredited laboratory with pretest and post-test support. A result may be positive, a true negative for a known family variant, uninformative negative or uncertain. Each has different implications. Tumour testing can identify a BRCA change that arose only in the cancer, so germline confirmation may be needed before drawing conclusions about relatives [1][4].

  • Bring consumer-test reports to a genetics professional rather than relying on an app summary.
  • Confirm tumour findings with germline testing when indicated.
  • Document exactly which genes and variant types a test assessed.

Cascade testing converts knowledge into prevention

When a pathogenic family variant is identified, targeted testing can be offered to adult blood relatives. This is cascade testing. A relative who tests negative for the known family variant can usually avoid the intensified management associated with that variant, while a relative who tests positive can consider earlier surveillance, medicines or risk-reducing surgery according to gene-specific guidance [1][5].

The person who receives the first result should not be left to act as the family's genetic service. Clinics can provide plain-language letters, translated materials and consent-based support for communication. Privacy law generally prevents clinicians from contacting relatives without permission, and legal rules differ. Family communication should be encouraged without coercion or blame.

  • Give the family the exact gene, variant and laboratory classification.
  • Offer a letter relatives can take to their own clinicians.
  • Track whether relatives reached counselling without exposing identities unnecessarily.

Risk management is personalised and time-sensitive

Options for a confirmed harmful BRCA variant can include earlier breast MRI and mammography, risk-reducing medicines, mastectomy and salpingo-oophorectomy, with timing based on gene, age, family history, fertility goals and patient preference [1][2]. There is no effective ovarian-cancer screening method known to reduce mortality, even for BRCA carriers, so surveillance tests should not be presented as equivalent to proven risk-reducing strategies [1].

Decision support should show absolute risk ranges, consequences for fertility and menopause, residual risk and alternatives. A digital pedigree can surface eligible relatives and overdue review, but genetic data are identifying and relevant to family members. Access, retention, research use and sharing require explicit governance. The aim is informed prevention, not maximum intervention.

  • Review fertility and menopause implications before risk-reducing surgery.
  • Revisit plans as guidelines, age and family circumstances change.
  • Protect genetic information with granular consent and access controls.

What the evidence cannot yet answer

  • Risk estimates are population ranges and vary by gene, variant, ancestry, family history and study design.
  • A variant of uncertain significance is not evidence of inherited cancer predisposition and may later be reclassified.
  • Access to counselling, testing and preventive interventions is uneven, and cascade-testing uptake is incomplete.

Questions worth taking into care

  1. Who in the family is the most informative person to test first?
  2. What genes and variant types will the laboratory analyse?
  3. How would each possible result change medical management?
  4. How will relatives receive accurate information and targeted testing?
  5. How are fertility goals, menopause consequences and privacy included in the plan?

Source record

Evidence used in this review

Sources were selected for clinical authority, methodological relevance and traceability. Links open the original guidance, public-health record or research publication.

  1. [1]
  2. [2]
  3. [3]
    Genetics of Breast and Gynecologic Cancers

    National Cancer Institute · 2025

  4. [4]
    Genetic Testing Fact Sheet

    National Cancer Institute · 2024

  5. [5]
    About Cascade Testing

    Centers for Disease Control and Prevention · 2024

  6. [6]
    Genetic Testing for Hereditary Breast and Ovarian Cancer

    Centers for Disease Control and Prevention · 2024

Editorial standard

This evidence synthesis is for general information. It does not diagnose a condition or replace care from a qualified health professional. Treatment choices depend on individual history, examination, local guidance and informed preference. Emergency or rapidly worsening symptoms need urgent local medical assessment.